Primary aldosteronism

Primary aldosteronism
Name	Primary aldosteronism
Field	Endocrinology
Symptoms	Hypertension, hypokalemia
Complications	Stroke, myocardial infarction, kidney disease
Onset	Adult
Causes	Aldosterone-producing adenoma, bilateral adrenal hyperplasia
Diagnosis	Aldosterone-to-renin ratio, adrenal imaging, adrenal venous sampling
Treatment	Mineralocorticoid receptor antagonists, adrenalectomy

Primary aldosteronism is an endocrine disorder characterized by autonomous overproduction of aldosterone from the adrenal cortex, leading to hypertension and metabolic disturbances. It was first described in detail in the context of secondary hypertension research and has been the subject of major clinical guidelines from institutions such as the World Health Organization, National Institutes of Health, and national endocrine societies. The condition has implications across cardiovascular medicine and nephrology, intersecting with care paradigms from organizations like the American Heart Association, European Society of Cardiology, and American College of Physicians.

Introduction

Primary aldosteronism emerges when the zona glomerulosa of the adrenal cortex secretes excess aldosterone independent of regulatory signals, producing sodium retention, potassium loss, and volume expansion. Historically studied by investigators connected to Harvard Medical School, Mayo Clinic, and Massachusetts General Hospital, the disorder has been linked with increased cardiovascular risk compared with essential hypertension of similar severity. Epidemiological studies from centers including Johns Hopkins Hospital, Cleveland Clinic, and Karolinska Institute have refined prevalence estimates and influenced screening recommendations from agencies like the United States Preventive Services Task Force and national endocrine societies.

Signs and symptoms

Patients commonly present with resistant hypertension, episodic muscle weakness, and paresthesia related to hypokalemia, findings emphasized in case series from Mount Sinai Hospital, University College London Hospitals, and Stanford Health Care. On examination, clinicians from institutions such as Imperial College London and University of California, San Francisco document features of sustained blood pressure elevation and sometimes signs of target-organ damage consistent with reports from Brigham and Women's Hospital and Guy's and St Thomas' NHS Foundation Trust. Laboratory abnormalities often include suppressed plasma renin activity and elevated serum aldosterone, a pattern noted in cohort studies at Mayo Clinic and Royal Prince Alfred Hospital.

Pathophysiology

The principal mechanisms involve aldosterone-producing adenomas (Conn's syndrome) or bilateral adrenal hyperplasia, described in classic reports from researchers at University of Pennsylvania, University of Oxford, and University of Tokyo. Molecular insights from laboratories affiliated with Cold Spring Harbor Laboratory, Max Planck Institute, and Salk Institute have identified somatic mutations in genes such as KCNJ5 and CACNA1D that drive autonomous aldosterone synthesis, paralleling discoveries reported by groups at Johns Hopkins University, Imperial College London, and University of Cambridge. The resulting mineralocorticoid receptor activation leads to sodium retention and potassium excretion with downstream effects on cardiac remodeling highlighted in translational work from Cleveland Clinic and Mayo Clinic.

Diagnosis

Screening typically employs an aldosterone-to-renin ratio, a protocol standardized by multicenter collaborations involving American Endocrine Society task forces, European Society of Endocrinology, and research consortia at NIH Clinical Center and Vanderbilt University Medical Center. Confirmatory testing, including saline infusion, oral sodium loading, or fludrocortisone suppression, has been validated in studies from Massachusetts General Hospital and University of California, Los Angeles. Imaging with computed tomography of the adrenal glands and adrenal venous sampling for lateralization are procedures performed in tertiary centers such as Mount Sinai Hospital, Mayo Clinic, and Karolinska University Hospital to distinguish unilateral adenoma from bilateral hyperplasia, techniques refined through collaborations with interventional radiology teams at Cleveland Clinic and Johns Hopkins Hospital.

Differential diagnosis

Important alternatives include secondary causes of mineralocorticoid excess such as renovascular hypertension from renal artery stenosis, apparent mineralocorticoid excess syndromes, and medication-induced causes, considerations reflected in reviews from Cleveland Clinic, Brigham and Women's Hospital, and Guy's and St Thomas' NHS Foundation Trust. Endocrine mimics such as Cushing's syndrome and pheochromocytoma are often excluded through testing strategies developed at Mayo Clinic, Stanford Health Care, and Johns Hopkins Hospital, while hereditary forms of hyperaldosteronism have been delineated by geneticists at University of Cambridge, University of Oxford, and University of Bonn.

Treatment

Definitive management depends on etiology: laparoscopic unilateral adrenalectomy is recommended for aldosterone-producing adenoma, a surgical approach popularized in series from Mayo Clinic, Massachusetts General Hospital, and Cleveland Clinic. For bilateral adrenal hyperplasia, medical therapy with mineralocorticoid receptor antagonists such as spironolactone or eplerenone is standard care, drugs studied in multicenter trials involving National Institutes of Health, European Medicines Agency, and academic centers including Imperial College London and Vanderbilt University Medical Center. Adjunctive antihypertensive strategies draw on guidelines from the American Heart Association and the European Society of Cardiology, and perioperative care often follows pathways developed at institutions like Johns Hopkins Hospital and Mount Sinai Hospital.

Prognosis and outcomes

Outcomes vary by timely recognition and treatment; patients undergoing adrenalectomy often experience biochemical cure and improved blood pressure control, outcomes reported by centers such as Mayo Clinic and Massachusetts General Hospital. Long-term cardiovascular risk reduction has been demonstrated in cohort studies from Johns Hopkins University, Karolinska Institute, and Cleveland Clinic, though residual risk persists if diagnosis is delayed, a theme echoed in public health analyses from the World Health Organization and national health agencies. Multidisciplinary follow-up in clinics modeled on programs at Vanderbilt University Medical Center and Stanford Health Care is recommended to optimize renal and cardiovascular outcomes.

Category:Endocrinology